SpaceOAR® Hydrogel Application Video -Marcio Fagundes

SpaceOAR® System Application with Dr. Fagundes (Full Procedure)

(Length of video -  10 minutes)

Dr. Marcio Fagundes, Medical Director and Vice Chair at Miami Cancer Institute at Baptist Health South Florida, presents the technique to inject SpaceOAR® or hydrogel between the prostate and the rectum via a transfer needle approach.  The full procedure is demonstrated starting with pre-application prep with a local anesthesia approach.  While allowing sufficient time for the lidocaine to take effect the SpaceOAR® device is prepped and assembled.  Dr. Fagundes completes the SpaceOAR® procedure ensuring the gel dispersed and has good dissipation from base to apex.

SpaceOAR® System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceOAR® System to reduce the radiation dose delivered to the anterior rectum. The SpaceOAR® System is composed of biodegradable material and maintains space for the entire course of prostate radiotherapy treatment and is completely absorbed by the patient’s body over time.

Biography:

Marcio Fagundes, MD. Medical Director and Vice Chair at Miami Cancer Institute at Baptist Health South Florida, Board-certified radiation oncologist. Particle Therapy Co-Operative Group, American Society of Therapeutic Radiation Oncologists. 

Dr. Fagundes received his medical degree from Universidade Federal do Rio Grande do Sul in Porto Alegre, Brazil, and completed a radiation oncology residency at the University of Miami Miller School of Medicine/Jackson Memorial Hospital – Sylvester Comprehensive Cancer Center. He also completed a fellowship in radiation oncology at Harvard Medical School/ Massachusetts General Hospital in Boston. He gained teaching experience as an assistant professor of radiation oncology at Tufts University School of Medicine in Boston, and currently trains his peers on an innovative treatment protocol for prostate cancer.

More Related Content:

Augmenix® Announces Medicare Reimbursement Rates, Effective January 2018

Hydrogel injection reduces rectal toxicity after radiotherapy for localized prostate cancer.

Watch: Hydrogel Spacer Prospective Pivotal Trial - Neil Mariados